Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma

British Journal of Haematology
Frank VariDerek N J Hart

Abstract

Therapeutic vaccination combined with new drugs may cure multiple myeloma (MM). We have developed a bio-process to purify CMRF-56 monoclonal antibody (mAb) and a standard operating procedure to immunoselect blood dendritic cells (BDC). Leucopheresed mononuclear cells were cultured overnight, labelled with CMRF-56 mAb and BDC prepared using a clinical scale immunoselection system. The mean BDC yield from healthy donors was 48% (n = 6, purity 28%). Preparations from MM patients (n = 6, yield 47%, purity 35%) primed cytotoxic T lymphocytes (CTL) to clinically relevant MM antigens. This procedure can be performed readily by clinical cell manufacturing units to facilitate BDC vaccination studies.

References

Nov 13, 1998·Biologicals : Journal of the International Association of Biological Standardization·H Aranha-CreadoP Y Huang
Jul 14, 1999·Biologicals : Journal of the International Association of Biological Standardization·O J BosJ Over
Mar 1, 2003·Journal of Immunological Methods·J Alejandro LópezDerek N J Hart
Jan 24, 2004·Current Drug Targets·C J Turtle, D N J Hart
Dec 24, 2005·Pathology·Kristen J RadfordDerek N J Hart
Sep 19, 2006·The Lancet Oncology·Paula Gould
Mar 31, 2007·Nature Reviews. Drug Discovery·Matthew Strobeck
Nov 27, 2007·Advances in Cancer Research·Annelie VulinkDerek N J Hart
Dec 7, 2007·Critical Reviews in Oncology/hematology·Alessio NencioniPeter Brossart

❮ Previous
Next ❯

Citations

Oct 10, 2012·American Journal of Hematology·Akiyoshi MiwaKen Yanagisawa
Aug 5, 2015·Pharmacological Reviews·Sébastien AnguilleZwi N Berneman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.